Agendia: Ronald Andrews, David Schreiber
Agendia has appointed Ronald Andrews and David Schreiber to its board of directors. Andrews most recently served as a board member, president, and CEO of Oncocyte. Prior to that he held senior roles at Thermo Fisher and was CEO and vice chairman of the board of Clarient. Andrews also founded consulting firm The Bethesda Group and held management positions at Roche Molecular Diagnostics, Immucore, and Abbott Diagnostics. He has served on the boards of Insight Genetics, Precipio, and Oxford ImmunoTec, and is a member of the board of governors of the American Society of Clinical Oncology's CancerLinQ.
Schreiber boasts close to 40 years of experience in the laboratory diagnostics space, working for over two decades as a consultant to private equity firms focused on healthcare companies in their portfolios. Prior to this, he served as CFO of Dianon Systems and worked at Quest Diagnostics. He holds an MBA and a BS in finance from Northern Illinois University, and has served on the boards of several companies including Specialty Labs, Nanogen, Response Genetics, and Aspira Women's Health.